NCT03560362

Postoperative Pain Control With Lipossomic Extended Release Bupivacaine

Randomized Trial Comparing Bupivacaine vs Lipossomic Extended Release Bupivacaine for Postoperative Pain Control After Minimally Invasive Thoracic Surgery

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: University of Tennessee · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Randomized trial of intraoperative intercostal block with bupivacaine with epinephrine compared to lipossomal extended release bupivacaine.

Detailed description

Patients undergoing minimally invasive thoracic surgery will be randomized to receive 0.05% bupivacaine with 1:200,000 epinephrine (control group) or extended release lipossomal bupivacaine. Primary outcomes are postoperative pain measured by visual analog scale, amount of morphine equivalent narcotics used, and postoperative complications. Patients are excluded if they undergo open thoracotomy, or minimally invasive decortication.

Conditions

• Pain, Postoperative
• Lung Cancer

Interventions

Type	Name	Description
DRUG	Bupivacaine liposome
DRUG	Bupivacaine / Epinephrine

Timeline

• Start date: 2015-07-09
• Primary completion: 2018-10-31
• Completion: 2018-10-31
• First posted: 2018-06-18
• Last updated: 2018-06-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study